245 related articles for article (PubMed ID: 19142186)
1. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
[TBL] [Abstract][Full Text] [Related]
2. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
3. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
5. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.
Karkoulis PK; Stravopodis DJ; Margaritis LH; Voutsinas GE
BMC Cancer; 2010 Sep; 10():481. PubMed ID: 20828379
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
Li Y; Zhang T; Schwartz SJ; Sun D
Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
[TBL] [Abstract][Full Text] [Related]
7. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
[TBL] [Abstract][Full Text] [Related]
8. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG.
Hadley KE; Hendricks DT
BMC Cancer; 2014 May; 14():334. PubMed ID: 24886060
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice.
Sun J; Liu L; Jiang X; Chen D; Huang Y
Cancer Biother Radiopharm; 2010 Apr; 25(2):155-64. PubMed ID: 20423228
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
[TBL] [Abstract][Full Text] [Related]
11. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.
Khaledian B; Taguchi A; Shin-Ya K; Kondo-Ida L; Kagaya N; Suzuki M; Kajino T; Yamaguchi T; Shimada Y; Takahashi T
Cancer Sci; 2021 Mar; 112(3):1225-1234. PubMed ID: 33370472
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
14. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N
Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
[TBL] [Abstract][Full Text] [Related]
16. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
Giubellino A; Sourbier C; Lee MJ; Scroggins B; Bullova P; Landau M; Ying W; Neckers L; Trepel JB; Pacak K
PLoS One; 2013; 8(2):e56083. PubMed ID: 23457505
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
Huntoon CJ; Nye MD; Geng L; Peterson KL; Flatten KS; Haluska P; Kaufmann SH; Karnitz LM
Cancer Res; 2010 Nov; 70(21):8642-50. PubMed ID: 20841485
[TBL] [Abstract][Full Text] [Related]
18. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
Okamoto J; Mikami I; Tominaga Y; Kuchenbecker KM; Lin YC; Bravo DT; Clement G; Yagui-Beltran A; Ray MR; Koizumi K; He B; Jablons DM
J Thorac Oncol; 2008 Oct; 3(10):1089-95. PubMed ID: 18827603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
